Literature DB >> 3006296

Visceral leishmaniasis unresponsive to antimonial drugs. III. Successful treatment using a combination of sodium stibogluconate plus allopurinol.

C N Chunge, G Gachihi, R Muigai, K Wasunna, J R Rashid, J D Chulay, G Anabwani, C N Oster, A D Bryceson.   

Abstract

Five patients with long-standing visceral leishmaniasis who were unresponsive to sodium stibogluconate, 20 mg antimony/kg body-weight once or twice daily, were treated for 14 to 54 days with a combination of sodium stibogluconate at the same dose plus allopurinol at a dose of 20 mg/kg body-weight per day in three divided doses. This combination was safe and effective. Negative splenic aspirate smears were obtained from all patients within 19 days, and none has relapsed in at least 12 months of follow-up.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3006296     DOI: 10.1016/0035-9203(85)90200-7

Source DB:  PubMed          Journal:  Trans R Soc Trop Med Hyg        ISSN: 0035-9203            Impact factor:   2.184


  20 in total

1.  Antileishmanial drug targeting through glycosylated polymers specifically internalized by macrophage membrane lectins.

Authors:  E Nègre; M L Chance; S Y Hanboula; M Monsigny; A C Roche; R M Mayer; M Hommel
Journal:  Antimicrob Agents Chemother       Date:  1992-10       Impact factor: 5.191

2.  In vitro and in vivo interactions between miltefosine and other antileishmanial drugs.

Authors:  Karin Seifert; Simon L Croft
Journal:  Antimicrob Agents Chemother       Date:  2006-01       Impact factor: 5.191

Review 3.  Drug resistance in leishmaniasis.

Authors:  Simon L Croft; Shyam Sundar; Alan H Fairlamb
Journal:  Clin Microbiol Rev       Date:  2006-01       Impact factor: 26.132

4.  An axenic amastigote system for drug screening.

Authors:  H L Callahan; A C Portal; R Devereaux; M Grogl
Journal:  Antimicrob Agents Chemother       Date:  1997-04       Impact factor: 5.191

Review 5.  Interventions for Old World cutaneous leishmaniasis.

Authors:  Julio Heras-Mosteiro; Begoña Monge-Maillo; Mariona Pinart; Patricia Lopez Pereira; Ludovic Reveiz; Emely Garcia-Carrasco; Pedro Campuzano Cuadrado; Ana Royuela; Irene Mendez Roman; Rogelio López-Vélez
Journal:  Cochrane Database Syst Rev       Date:  2017-11-17

Review 6.  Leishmania and human immunodeficiency virus coinfection: the first 10 years.

Authors:  J Alvar; C Cañavate; B Gutiérrez-Solar; M Jiménez; F Laguna; R López-Vélez; R Molina; J Moreno
Journal:  Clin Microbiol Rev       Date:  1997-04       Impact factor: 26.132

7.  Suppression of Leishmania donovani by oral administration of a bis(benzyl)polyamine analog.

Authors:  R J Baumann; P P McCann; A J Bitonti
Journal:  Antimicrob Agents Chemother       Date:  1991-07       Impact factor: 5.191

Review 8.  Leishmaniases of the New World: current concepts and implications for future research.

Authors:  G Grimaldi; R B Tesh
Journal:  Clin Microbiol Rev       Date:  1993-07       Impact factor: 26.132

9.  Hexadecylphosphocholine: oral treatment of visceral leishmaniasis in mice.

Authors:  A Kuhlencord; T Maniera; H Eibl; C Unger
Journal:  Antimicrob Agents Chemother       Date:  1992-08       Impact factor: 5.191

10.  Experimental visceral leishmaniasis: role of trans-aconitic acid in combined chemotherapy.

Authors:  S Kar; K Kar; P K Bhattacharya; D K Ghosh
Journal:  Antimicrob Agents Chemother       Date:  1993-11       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.